SEC Form 4 · accession 0001347383-26-000003
Evommune, Inc. · EVMN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David E Cohen
Director
Period of report
Jun 2, 2026
Accepted (ET)
Jun 3, 2026 · 8:03 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0002044725
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 2, 2026 | S | 5,456 | $20.21 | D | 18,209 | D | |
| Common StockF3 | Jun 2, 2026 | S | 600 | $21.38 | D | 17,609 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy)F4 | $19.82 | Jun 2, 2026 | A | 15,673 | A | — | Jun 1, 2036 | Common Stock | 15,673 | 15,673 | D |
Explanation of responses
- F1The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026.
- F2The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $20.00 to $20.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- F3The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.06 to $21.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- F4The shares subject to the option award shall vest at the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.